Insomnia Treatment
Cognitive-behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia in adults and should be initiated before considering pharmacological interventions. 1, 2
Treatment Algorithm
Step 1: Initial Treatment - CBT-I
- Start with multicomponent CBT-I as the primary intervention, delivered either in-person or digitally 1, 2
- CBT-I has demonstrated superior long-term durability compared to medications, with sustained benefits after treatment discontinuation 3
- This recommendation applies to all adults regardless of age and includes patients with medical or psychiatric comorbidities 2
Key advantage: CBT-I provides durable effects that persist after treatment ends, unlike pharmacological options which lose efficacy upon discontinuation 3
Step 2: When CBT-I is Insufficient or Unavailable
If CBT-I proves ineffective after an adequate trial or is not accessible, pharmacological treatment can be offered 2. The 2017 AASM guideline emphasized that medications should be considered primarily in three scenarios:
- Patients unable to participate in CBT-I
- Residual symptoms following adequate CBT-I trial
- Temporary adjunct to CBT-I in select cases 1
Step 3: Pharmacological Options
For short-term use (≤4 weeks):
- Sleep onset insomnia: Triazolam, ramelteon, or zaleplon 1
- Sleep maintenance insomnia: Low-dose doxepin or suvorexant 1, 4
- Combined onset and maintenance: Temazepam, zolpidem, or eszopiclone 1
- Benzodiazepines and benzodiazepine receptor agonists are appropriate for this duration 2
For longer-term use (up to 3 months or more):
- Orexin receptor antagonists (including newer agents like daridorexant and lemborexant) can be used for 3 months or longer in selected cases 2, 1
- Prolonged-release melatonin for patients ≥55 years (up to 3 months) 2
- Longer-term benzodiazepines/BZRAs may be appropriate in some cases after careful individual risk-benefit assessment 2
Step 4: Combination Treatment Considerations
The 2026 AASM combination treatment guideline addresses a critical gap: while combining CBT-I with medication may decrease latency to treatment response, it might diminish the durability of CBT-I's positive effects 3. Use combination therapy judiciously and primarily as a temporary bridge rather than long-term strategy.
What NOT to Use
Conditional recommendations AGAINST the following due to insufficient efficacy evidence, absence of high-quality data, or safety concerns 1, 2:
- Trazodone
- Tiagabine
- Diphenhydramine and other antihistamines
- Melatonin (fast-release formulations)
- Tryptophan
- Valerian
- Antipsychotics
- Ramelteon (per European guidelines)
- Sleep hygiene as a single-component therapy 1
Critical Clinical Pitfalls
Common mistake: Using sleep hygiene education alone as treatment. While necessary, sleep hygiene measures are insufficient when used in isolation and received a conditional recommendation against single-component use 1, 5
Important caveat: Although guidelines are based on daily medication use as evaluated in randomized trials, clinical practice may involve non-nightly use for patients who don't require nightly treatment 6
Diagnosis reminder: Clinical diagnosis based on careful history using ICSD or DSM criteria is sufficient; objective sleep testing is only needed when suspecting comorbid sleep disorders like sleep apnea 1
Rationale for CBT-I Priority
The strong preference for CBT-I over pharmacotherapy is evidence-based:
- Patients prefer behavioral-psychological treatments due to perceived better long-term efficacy
- Provides more benefits for daytime symptoms
- Has fewer side effects compared to medications 1
- Shows durable effects that persist after treatment discontinuation, unlike medications 3
The treatment hierarchy is clear: CBT-I first, medications second, and combination therapy reserved for specific clinical scenarios where monotherapy proves inadequate.